Cogent Biosciences, Inc. COGT Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $241.21M+91.4% | $312.01M+218% | $125.3M+29.1% | $127.6M+44.6% | $126M-41.6% | ||
| $625.17M+422% | $588.75M+212% | $265.59M+11.4% | $110.25M-59.9% | $119.66M-45.6% | ||
| $416K— | $416K— | $336K— | —— | —— | ||
| $11.43M+58.2% | $9.59M+2.1% | $6.35M+5.7% | $7.16M+6.0% | $7.22M+17.2% | ||
| $877.8M+247% | $910.36M+207% | $397.24M+16.3% | $245.01M-33.8% | $252.88M-42.8% | ||
| $5.3M-17.9% | $5.46M-15.6% | $5.27M-24.8% | $5.85M-20.5% | $6.45M-17.4% | ||
| $17.55M-10.5% | $18.08M-10.0% | $18.59M-9.7% | $19.1M-9.3% | $19.6M-9.0% | ||
| $1.94M-60.1% | $3.3M-32.1% | $4.49M-7.7% | $4.86M0.0% | $4.86M0.0% | ||
| $903.01M+218% | $937.61M+186% | $425.93M+10.9% | $274.82M-36.1% | $283.8M-40.4% | ||
| $13.74M-2.9% | $9.5M-20.9% | $16.03M+6.4% | $16.63M+85.2% | $14.15M-9.1% | ||
| $1.38M-14.2% | $1.55M-1.2% | $1.71M+12.2% | $1.66M+12.4% | $1.61M+12.5% | ||
| $57.98M+17.6% | $63.95M+14.8% | $62.25M+17.3% | $58.42M+46.0% | $49.32M+34.4% | ||
| $14.1M-8.9% | $14.36M-9.7% | $14.6M-10.5% | $15.05M-9.9% | $15.48M-9.4% | ||
| $62K+1,140% | $33K— | $2.37M— | $2.36M— | $5K— | ||
| $295.31M+356% | $301.24M+321% | $123.47M+78.0% | $119.78M+111% | $64.8M+20.5% | ||
| $171K+50.0% | $161K+46.4% | $141K+28.2% | $114K+4.6% | $114K+18.8% | ||
| $1.83B+75.5% | $1.73B+72.7% | $1.28B+28.7% | $1.05B+7.3% | $1.04B+20.9% | ||
| -$1.29B-38.0% | -$1.19B-38.3% | -$1.09B-37.2% | -$1B-39.4% | -$931.47M-40.7% | ||
| -$415K-353% | $355K-20.6% | $208K-76.8% | $13K+107% | $164K+521% | ||
| $607.69M+177% | $636.37M+148% | $302.46M-3.9% | $155.04M-58.5% | $219M-48.1% | ||
| $903.01M+218% | $937.61M+186% | $425.93M+10.9% | $274.82M-36.1% | $283.8M-40.4% | ||
| $625.17M+422% | $588.75M+212% | $265.59M+11.4% | $110.25M-59.9% | $119.66M-45.6% | ||
| $1.94M-60.1% | $3.3M-32.1% | $4.49M-7.7% | $4.86M0.0% | $4.86M0.0% | ||
| $17.55M-10.5% | $18.08M-10.0% | $18.59M-9.7% | $19.1M-9.3% | $19.6M-9.0% | ||
| $17.55M-10.5% | $18.08M-10.0% | $18.59M-9.7% | $19.1M-9.3% | $19.6M-9.0% | ||
| $1.94M-60.1% | $3.3M-32.1% | $4.49M-7.7% | $4.86M0.0% | $4.86M0.0% | ||
| $17.55M-10.5% | $18.08M-10.0% | $18.59M-9.7% | $19.1M-9.3% | $19.6M-9.0% | ||
| $1.94M-60.1% | $3.3M-32.1% | $4.49M-7.7% | $4.86M0.0% | $4.86M0.0% | ||
| $42.85M+27.7% | $52.9M+25.6% | $44.51M+22.1% | $40.14M+35.8% | $33.55M+70.4% | ||
| $223.17M— | $222.9M— | —— | —— | —— | ||
| $15.48M-9.4% | $15.9M-9.0% | $60.56M+240% | $60.66M+234% | $17.09M-7.7% | ||
| $1.83B+75.5% | $1.73B+72.7% | $1.28B+28.7% | $1.05B+7.3% | $1.04B+20.9% | ||
| $171K+50.0% | $161K+46.4% | $141K+28.2% | $114K+4.6% | $114K+18.8% | ||
| $223.17M— | $222.9M— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cogent Biosciences, Inc.'s total assets?
- Cogent Biosciences, Inc. (COGT) holds $903.0M in total assets, up 218.2% year over year.
- How much debt does Cogent Biosciences, Inc. have?
- Cogent Biosciences, Inc. carries $15.5M in total debt against $607.7M of shareholders' equity, a debt-to-equity ratio of 0.03.
- How much cash does Cogent Biosciences, Inc. have?
- Cogent Biosciences, Inc. holds $241.2M in cash and equivalents.
- Can Cogent Biosciences, Inc. cover its short-term obligations?
- Its current ratio is 15.14 — current assets exceed current liabilities.
- Where does Cogent Biosciences, Inc.'s balance sheet data come from?
- Every line is extracted from Cogent Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
